Abstract: Compositions containing extracellular vesicles (EVs) derived from a Faecalibacterium sp. strain are disclosed. The compositions can be used to prevent and/or treat cancer and/or ameliorate symptoms of cancer, and can be pharmaceutical composition, food stuffs, or dietary supplements. The compositions may contain a pharmaceutically acceptable carrier or excipient. The compositions exhibit an excellent effect on the prevention or treatment of cancer, or ameliorating symptoms of cancer.

Abstract: A pharmaceutical composition effective for the prevention or treatment of atopic disease is disclosed. The pharmaceutical composition contains a Faecalibacterium prausnitzii EB-FPDK11 strain or a culture or dried product thereof. While traditional probiotics generally have an insignificant therapeutic effect for atopic disease, the pharmaceutical composition of the present invention exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

Abstract: A pharmaceutical composition containing an Akkermansia muciniphila EB-AMDK19 strain or a culture or dried product thereof and uses thereof are disclosed. The composition is effective for the prevention or treatment of atopic disease. The pharmaceutical composition exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.